Incidence, risk factors, andmanagement of infusion-related reactions in breast cancer patients receiving trastuzumab

Oncologist

Volumn 19, Issue 3, 2014, Pages 228-234

  Thompson, Lisa M ^a   Eckmann, Karen ^b   Boster, Bonnie L ^b   Hess, Kenneth R ^b   Michaud, Laura B ^b   Esteva, Francisco J ^b   Hortobágyi, Gabriel N ^c   Barnett, Chad M ^b  

^a Banner MD Anderson Cancer Center   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Hypersensitivity; Infusion related reactions; Monoclonal antibodies; Trastuzumab

Indexed keywords

BEVACIZUMAB; DIPHENHYDRAMINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYDROCORTISONE; PACLITAXEL; PARACETAMOL; PETHIDINE; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER STAGING; CHILL; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE SEVERITY; DYSPNEA; ELECTRONIC MEDICAL RECORD; FEMALE; HEADACHE; HUMAN; HYPERSENSITIVITY; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; PAIN; PARESTHESIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIGOR; RISK FACTOR; VERY ELDERLY; VOMITING; BREAST NEOPLASMS; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84896468399     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0286     Document Type: Article

References (14)

1. Ross JS, Slodkowska EA, SymmansWFet al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009; 14: 320-368.
2. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61: 912-920.
3. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. The Oncologist 2008; 13: 725-732.
4. Herceptin [PackageInsert]. South SanFrancisco, CA: Genentech, Inc.; October 2010. http://www. gene. com/download/pdf/herceptin_prescribing. pdf Accessed May 23, 2013.
5. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. TheOncologist 2007; 12: 601-609.
6. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy inmetastatic breast cancer. Oncology 2001; 61(suppl 2): 58-66.
7. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
8. Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-2171.
9. Chan AS, Freeswick S, Sklarin NT. Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes. CancerRes2009; 69(2Suppl): Abstractnr3150.
10. Ring A, Simcock R, Mitra S et al. Infusion of trastuzumab maintenance doses over 30 minutes. Ann Oncol 2008; 19: 1509-1510.
11. National Cancer Institute Common Terminology Criteria forAdverse Events (CTCAE) v4. 03. Available at: http://ctep. cancer. gov/protocolDevelopment/electronic_applications/ctc. htm. Accessed September 8, 2010.
12. Parolin V, Fiorio E, Mercanti M et al. The prognostic and predictive impact of BMI on clinical outcome of HER2-positive breast cancer. J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no. 15_suppl 1130.
13. Crozier JA, Moreno-Aspitia A, Ballman KV et al. Correlation between BMI and clinical outcome of patientswithearly stageHER21breastcancer fromthe N9831 clinical trial. Cancer 2013 [E-pub ahead of print].
14. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-1333.